Synthesis of triazole derivatives as anti tubercular And anticancer agents

Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/1498

Full metadata record

DC Field	Value	Language
dc.contributor.author	Dr.Arnika Das, D01214007	-
dc.date.accessioned	2023-09-25T05:52:27Z	-
dc.date.available	2023-09-25T05:52:27Z	-
dc.date.issued	2023	-
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/1498	-
dc.description.abstract	Background: Cancer and tuberculosis are India’s biggest health concerns. The National Cancer Registry Program 2022 reports an estimated 14,61,427 cancer patients in India by 2025 while WHO finds India as the country with the maximum number of tuberculosis cases. The government of India vowed to eradicate TB by 2025. The chemotherapeutic agents available to treat cancer bear one or the other untoward effects. At the same time, the emergence of multi- drug resistance Mycobacterium strains are limiting the effectiveness of existing anti- tubercular drugs. Objectives: To design and develop1,2,3-triazole analogs as a lead against cancer and tuberculosis.	en_US
dc.language.iso	en_US	en_US
dc.publisher	KLE Academy of Higher Education and Research, Belagavi	en_US
dc.subject	Cancer; Tuberculosis; 1,2,3-Triazole; Stilbene; Indole; Cytotoxicity; Molecular Docking; 1TUB; 6P8Q.	en_US
dc.title	Synthesis of triazole derivatives as anti tubercular And anticancer agents	en_US
dc.type	Phd Thesis	en_US
Appears in Collections:	Faculty of Pharmacy

Files in This Item:

File	Description	Size	Format
Dr.Arnika Das_D01214007.pdf		19.85 MB	Adobe PDF	View/Open